Subject: An observational survey study to analyze management of Chronic obstructive pulmonary disease (COPD)
COPD is a chronic respiratory disease characterized by progressive and irreversible airway obstruction and is one of the major causes of morbidity and mortality worldwide.1
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019.2
The most common symptoms of COPD are difficulty breathing, chronic cough (sometimes with phlegm) and feeling tired. It can hamper routine physical activities like walking and climbing stairs.2
Smoking and air pollution are the most common causes of COPD. People with COPD also have a higher risk for other health problems. These include lung infections, like the flu or pneumonia, lung cancer, heart problem, weak muscles and brittle bones, depression and anxiety. 3
Clinicians commonly use various pharmacological treatments in the management of COPD relieve symptoms, improve quality of life, enhance exercise tolerance, prevent and treat exacerbations. The main strategy to be considered in the pharmacological treatment of COPD and asthma are bronchodilators; short-acting bronchodilators (β -agonist and anti- cholinergics) are given as first-line treatment and long-acting bronchodilators can be given in more symptomatic patients with greater functional impact.4
Airway mucus hypersecretion is one of the prominent features of severe respiratory diseases including asthma and COPD.5 Pharmacological approach for relieving mucus accumulation in airways currently involves several classes of agents, including mucolytics.5
A variety of drugs including inhalation formulations of corticosteroids, anti-histaminic, mucoregulatory agents etc. are used for medical management.
Hence, we designed the current study to analyze management of Chronic obstructive pulmonary disease (COPD)
If you agree to participate, you will need to fill data collection forms (which we call DCF).
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}